TUmeurs THYroïdiennes REFractaires.

Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer.

38. Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S 2016 

The Journal of clinical endocrinology and metabolism 101:2733-2741.

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.

37. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M 2016

The Journal of clinical endocrinology and metabolism 101:4103-4109.

Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.

14. Lamartina L, Borget I, Mirghani H, Al Ghuzlan A, Berdelou A, Bidault F, Deandreis D, Baudin E, Travagli JP, Schlumberger M, Hartl DM, Leboulleux S 2017

The Journal of clinical endocrinology and metabolism 102:1020-1031.

Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study.

28. Chereau N, Giudicelli X, Pattou F, Lifante JC, Triponez F, Mirallie E, Goudet P, Brunaud L, Tresallet C, Tissier F, Leenhardt L, du Montcel ST, Menegaux F 2016

The Journal of clinical endocrinology and metabolism 101:4603-4610.

 

En visitant notre site Web, vous acceptez que nous utilisions des cookies pour vous assurer d'obtenir la meilleure expérience.